Analysis of c-kit protein expression in pancreatic neoplasms and its implication for prognosis

Hepato-Gastroenterology

Volumn 54, Issue 80, 2007, Pages 2203-2208

  Kimura, Wataru ^a   Ma, Jinfeng ^a   Takeshita, Akiko ^a   Yamamoto, Takashi ^a   Moriya, Toshiyuki ^a   Hirai, Ichiro ^a   Fuse, Akira ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

c kit protein; Immunoreactive score; Pancreatic neoplasms

Indexed keywords

STEM CELL FACTOR RECEPTOR;

ARTICLE; CONTROLLED STUDY; ENDOCRINE CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PANCREAS DUCT; PANCREAS TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM;

ADENOCARCINOMA; CARCINOMA, PANCREATIC DUCTAL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; NEOPLASM INVASIVENESS; PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 37749036850     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Matsuno S, Egawa S, Fukuyama S, et al: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 2004; 28:219-230.
2. Siverberg E, Lubera J: Cancer statistics, 1987. CA Cancer J Clin 1988; 38:2-19.
3. Yeo CJ, Cameron JL, Sohn TA et al: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997; 226:248-257.
4. Howard JM: Development and progress in resective surgery for pancreatic cancer. World J Surg 1999; 23:901-906.
5. Kimura W, Nagai H, Kuroda A, et al: Analysis of small cystic lesions of the pancreas. Int J Pancreatol 1995; 18:197-206.
6. Kimura W, Sata N, Nakayama H, et al: Pancreatic carcinoma accompanied by pseudocyst: Report of two cases. J Gastroenterol 1994; 29:786-791.
7. Heinrich MC, Blanke CD, Druker BJ, Corless CL: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20:1692-1703.
8. Besmer P, Manova K, Duttlinger R, Huang EJ, Packer A, Gyssler C, Bachvarova RF: The kit-ligand (steel factor) and its receptor c-kit/W: pleiotropic roles in gameto-genesis and melanogenesis. Dev Suppl 1993; 125-137.
9. Hassan HT, Zander A: Stem cell factor as survival and growth factor in human normal and malignant hematopoiesis. Acta Haematol 1996; 95:257-262.
10. Ricotti E, Fagioli F, Garelli, E, Linari C, Crescenzio N, Horenstein AL, Pistamiglio P, Vai S, Berger M, di Montezemolo LC, Madon E, Basso G: C-KIT is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplasm cells. Blood 1998; 91:2397-2405.
11. Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD, Bar-Eli M: Enforced c-kit expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their neoplasmigenic and metastatic potential. Oncogene 1996; 13:2339-2347.
12. He J, deCastro CM, Vandenbark GR, Busciglio J, Gabuzda D: Astrocyte apoptosis induced by HIV-1 transactivation of the c-kit protooncogene. Proc Natl Acad Sci USA 1997; 94:3954-3959.
13. Nio Y, Omori H, Toga T, Hashimoto K, Itakura M, Koike M, Yano S, Higami T: Immunohistochemical expression of receptor-tyrosine kinase c-kit protein in invasive ductal carcinoma of the pancreas. Anticancer Drugs 2003; 14:313-319.
14. Esposito I, Kleeff J, Bischoff SC, Fischer L, Collecchi P, Iorio M, Bevilacqua G, Buchler MW, Friess H: The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab Invest. 2002; 82:1481-1492.
15. Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, Meyer T, Zimmermann J: Imatinib a selective tyrosine kinase inhibitor. Eur J Cancer 2002; 38:S19-S27.
16. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038-1042.
17. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R: Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal neoplasms. Clin Cancer Res 2002; 8:3034-3038.
18. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y, Takagi H, Takahashi T: Coexpression of the stem cell factor and the c-kit genes in small cell lung cancer. Oncogene 1991; 6:2291-2296.
19. Timeus F, Crescenzio N, Valle P, Pistamiglio P, Piglione M, Garelli E, Ricotti E, Rocchi P, Strippoli P, Cordero di Montezemolo L, Madon E, Ramenghi U, Basso G: Stem cell factor suppress apoptosis in neuroblastoma cell lines. Exp Hematol 1997; 25:1253-1260.
20. Natali PG, Nicotra MR, Sures I, Mottolese M, Botti C, Ullrich A: Breast cancer is associated with loss of the c-kit oncogene product. Int J Cancer 1992; 52:713-717.
21. Natali PG, Berlingieri MT, Nicotra MR, Fusco A, Santoro E, Bigotti A, Vecchio G: Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res 1995; 55:1787-1791.
22. Tonary AM, McDonald EA, Faugh W, Senterman MK, Vanderhyden BC: Lack of expression of c-kit in ovarian cancers is associated with poor prognosis. Int J Cancer 2000; 89:242-250.
23. Burger H, den Bakker MA, Stoter G, Verweij J, Nooter K: Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer 2003; 39:793-799.
24. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358:1421-1423.
25. Kimura W, Sasahira N, Yoshikawa T, Muto T, Makuuchi M: Duct-ectatic type of mucin producing neoplasm of the pancreas - new concept of pancreatic neoplasia. Hepatogastroenterology 1996; 43:692-709.
26. Kimura W, Kuroda A, Makuuchi M: Problems in the diagnosis and treatment of a so-called mucin-producing neoplasm of the pancreas. Pancreas 1998; 16:363-369.
27. Kimura W, Makuuchi M, Kuroda A: Characteristics and treatment of mucin-producing neoplasm of the pancreas. Hepatogastroenterology 1998; 45:2001-2008.
28. Kimura W: Cystic neoplasms of the pancreas - Diagnosis and therapy. Yamagata Med J 2000; 18:97-107.
29. Kimura W: IHPBA in Tokyo, 2002: Surgical treatment of IPMN vs MCN: a Japanese experience. J Hepatobiliary Pancreat Surg 2003; 10:156-162.
30. Li J, Kleeff J, Guo J, Fischer L, Giese N, Buchler MW, Friess H: Effects of STI571 (gleevec) on pancreatic cancer cell growth. Mol Cancer 2003; 2:32.
31. Zhang P, Gao WY, Turner S, Ducatman BS: Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2003; 2:1.
32. Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, Fidler IJ: Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 2003; 9:6534-6544.